Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Takeaways: The pCPA Letter of Intent for PrOKEDI (risperidone LAI) moves Bausch Health toward public reimbursement and broader access for Canada’s schizophrenia population, w...
